Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial

Document Type: Research Articles

Authors

1 Department of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Diabetes Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Food Security Research Center, Department of Clinical Nutrition, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Nutrition and Metabolic Disease Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

5 Infectious and Tropical Diseases Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

6 Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Background: Low levels of vitamin D are found in a great part of breast cancer women. Study subjects using vitamin
D3 supplement had lower rates of cancers and fewer markers of inflammation. Additionally, recent studies demonstrate
the power of vitamin D supplementation to lower inflammation and oxidative stress biomarkers associate with VDR
polymorphism to reduce inflammation. This study was aimed to assess the impact of vitamin D3 supplementation on
the serum concentration of inflammatory markers and antioxidant capacity with regard to VDR polymorphism in the
VDR gene in breast cancer women. Methods: A randomized, double-blind, placebo-controlled trial was conducted on 56
breast cancer women. Participants were assigned to 2 treatment arms: placebo and vitamin D3 for 2 months intervention.
Supplementation group received 50,000 IU of vitamin weekly. Blood samples were collected at baseline and after
the intervention to measure the 25(OH) D3, TNF-α, TGF- β and TAC. Genotyping was performed for FokI, BsmI, ApaI,
and TaqI polymorphism. Results: After eight weeks supplementation, the intervention group showed a significant increase
in the serum concentration of 25(OH) D3 (28±2.6 to 39±3.5; p=0.004 and TAC (48.9±13.3 to 63.5±13.3; p= 0.017).
Changes in TNF-α, TGF- β1 were not significant. Serum TAC levels of participants with the TT/Tt, Ff genotypes were
more responsive to supplementation. Conclusions: Supplementation with a vitamin D3 increased the TAC in breast
cancer women, although it had no effect on inflammatory markers. Serum TAC in the TT/Tt, Ff were more responsive to
vitamin D supplement compared with those with the FF/ff and tt genotypes.

Keywords

Main Subjects